 Home > Active Ingredient News > Antitumor Therapy > FDA approves Opdivo in joint Cabometyx for the treatment of advanced renal cell carcinoma

FDA approves Opdivo in joint Cabometyx for the treatment of advanced renal cell carcinoma

 Last Update: 2021-01-29
 Source: Internet
 Author: User

Tags

rm 8 18

jurkat cell line

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The U.S. Food and Drug Administration (FDA) said recently that it has approved a joint first-line treatment for patients with advanced renal cell carcinoma (RCC) using the anti-PD-1 antibody Opdivo (nivolumab) and Exelixis' tyrosine kinase inhibitor Cabozantinib.
decision was supported by data from the CheckMate-9ER III trial, which evaluated the effectiveness of Opdivo in previously untreated late-stage or metastasis RCC patients compared to Pfizer's Sunitinib.
, published in the European Society of Medical Oncology (ESMO) in 2020, showed that after a medium follow-up of 18.1 months, the progress-free survival of patients in the Opdivo combined Cabometyx group was 16.6 months, while the progress-free survival of patients in the Sutt group was only 8.3 months.
, Opdivo and Cabometyx also significantly reduced the risk of death by 40 percent compared to using Sutt alone.
kidney cell carcinoma (RCC) is a type of kidney cancer that is produced in small mucous membranes in the kidneys.
, a tumor grows in a single form, but sometimes more than one tumor may appear in one or both kidneys.
cancer is the most common type of kidney cancer in adults and tends to have the greatest impact on men between the ages of 50 and 70.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

High Quality Resveratrol 99% powder 501-36-0 Shaanxi Dideu Medichem Co.Ltd

CAS No.: 501-36-0

Chemical Grade

$1/KG FOB

High purity Epirubicin hydrochloride 98% with best price 56390-09-1 and Epirubicin hydrochloride raw powder

CAS No.: 56390-09-1

Pharmacy Grade

$8.8-10/MT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.